7.3 Regulation of necroptosis by natural products Research on the role of necroptosis in DOR and its potential therapeutic targeting through natural products remains limited
Obesity is a leading risk for higher medical costs, disability claims, absenteeism, and productivity loss
To further clarify the pathway by which EA activates NTS GLP1 , we employed taVNS as a positive control to assess the comparative efficacy between EA and taVNS in addressing obesity and modulating the excitability of vagal afferent fibers (Fig
GLP-1 medications, on the other hand, directly target appetite regulation, insulin response, and energy balance
The FDA advises that compounded medications should only be used when a healthcare provider determines there is a clinical need or during drug shortages
Fatigue: Feeling tired or lacking energy, usually occurring early in treatment and subsiding as the body adjusts